Patents by Inventor Denise Mazess Herpai

Denise Mazess Herpai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AGAINST HUMAN AND CANINE IL-13RA2
    Publication number: 20230295317
    Abstract: Provided herein are monoclonal antibodies that specifically bind IL-13RA2 with cross-reactivity in humans and canines. Also provided are methods of use of the antibodies in the treatment and monitoring of cancers.
    Type: Application
    Filed: April 11, 2023
    Publication date: September 21, 2023
    Inventors: Waldemar Debinski, Denise Mazess Herpai
  • Antibodies against human and canine IL-13RA2
    Patent number: 11655299
    Abstract: Provided herein are monoclonal antibodies that specifically bind IL-13RA2 with cross-reactivity in humans and canines. Also provided are methods of use of the antibodies in the treatment and monitoring of cancers.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: May 23, 2023
    Assignee: Wake Forest University Health Sciences
    Inventors: Waldemar Debinski, Denise Mazess Herpai
  • MOLECULAR SIGNATURE OF CANCER
    Publication number: 20220062376
    Abstract: The present invention provides compounds, compositions, and methods for detecting, diagnosing and treating cancers such as glioblastoma multiforme.
    Type: Application
    Filed: November 16, 2021
    Publication date: March 3, 2022
    Inventors: Waldemar Debinski, Jill Wykosky, Denise Mazess Herpai
  • Molecular signature of cancer
    Patent number: 11207380
    Abstract: The present invention provides compounds, compositions, and methods for detecting, diagnosing and treating cancers such as glioblastoma multiforme.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: December 28, 2021
    Assignee: Wake Forest University Health Sciences
    Inventors: Waldemar Debinski, Jill Wykosky, Denise Mazess Herpai
  • ANTIBODIES AGAINST HUMAN AND CANINE IL-13RA2
    Publication number: 20200299394
    Abstract: Provided herein are monoclonal antibodies that specifically bind IL-13RA2 with cross-reactivity in humans and canines. Also provided are methods of use of the antibodies in the treatment and monitoring of cancers.
    Type: Application
    Filed: May 5, 2020
    Publication date: September 24, 2020
    Inventors: Waldemar Debinski, Denise Mazess Herpai
  • Antibodies against human and canine IL-13RA2
    Patent number: 10676529
    Abstract: Provided herein are monoclonal antibodies that specifically bind IL-13RA2 with cross-reactivity in humans and canines. Also provided are methods of use of the antibodies in the treatment and monitoring of cancers.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: June 9, 2020
    Assignee: Wake Forest University Health Sciences
    Inventors: Waldemar Debinski, Denise Mazess Herpai
  • MOLECULAR SIGNATURE OF CANCER
    Publication number: 20180243368
    Abstract: The present invention provides compounds, compositions, and methods for detecting, diagnosing and treating cancers such as glioblastoma multiforme.
    Type: Application
    Filed: April 19, 2018
    Publication date: August 30, 2018
    Inventors: Waldemar Debinski, Jill Wykosky, Denise Mazess Herpai
  • ANTIBODIES AGAINST HUMAN AND CANINE IL-13RA2
    Publication number: 20180155437
    Abstract: Provided herein are monoclonal antibodies that specifically bind IL-13RA2 with cross-reactivity in humans and canines. Also provided are methods of use of the antibodies in the treatment and monitoring of cancers.
    Type: Application
    Filed: December 8, 2017
    Publication date: June 7, 2018
    Inventors: Waldemar Debinski, Denise Mazess Herpai
  • Molecular signature of cancer
    Patent number: 9974830
    Abstract: The present invention provides compounds, compositions, and methods for detecting, diagnosing and treating cancers such as glioblastoma multiforme.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: May 22, 2018
    Assignee: Wake Forest University Health Sciences
    Inventors: Waldemar Debinski, Jill Wykosky, Denise Mazess Herpai
  • IL-13 receptor binding peptides
    Patent number: 9878013
    Abstract: A targeting peptide that specifically binds to an IL13 receptor (e.g., wherein said targeting peptide is not an IL13 fragment) is described. The targeting peptide is optionally conjugated to at least one effector molecule. In some embodiments, the peptide specifically binds to the IL13R?2 protein.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: January 30, 2018
    Assignee: Wake Forest University Health Sciences
    Inventors: Waldemar Debinski, Hetal Pandya, Denise Mazess Herpai
  • Antibodies against human and canine IL-13RA2
    Patent number: 9868788
    Abstract: Provided herein is an antibody (e.g., an isolated antibody) that specifically binds an epitope (e.g., linear epitope) within amino acids spanning the extracellular portion of human IL-13RA2. In some embodiments, the amino acids spanning the extracellular portion of human IL-13RA2 have at least 90% identity with the corresponding canine sequence of IL-13RA2. In some embodiments, the antibody specifically binds both human and canine IL-13RA2. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a recombinant antibody. In some embodiments, the antibody is humanized. In some embodiments, the antibody is the monoclonal antibody produced by hybridoma 1E10B9 or a recombinant form thereof.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 16, 2018
    Assignee: Wake Forest University Health Sciences
    Inventors: Waldemar Debinski, Denise Mazess Herpai
  • MOLECULAR SIGNATURE OF CANCER
    Publication number: 20160193289
    Abstract: The present invention provides compounds, compositions, and methods for detecting, diagnosing and treating cancers such as glioblastoma multiforme.
    Type: Application
    Filed: February 9, 2016
    Publication date: July 7, 2016
    Inventors: Waldemar Debinski, Jill Wykosky, Denise Mazess Herpai
  • IL-13 RECEPTOR BINDING PEPTIDES
    Publication number: 20160175399
    Abstract: A targeting peptide that specifically binds to an IL13 receptor (e.g., wherein said targeting peptide is not an IL13 fragment) is described. The targeting peptide is optionally conjugated to at least one effector molecule. In some embodiments, the peptide specifically binds to the IL13R?2 protein.
    Type: Application
    Filed: February 17, 2016
    Publication date: June 23, 2016
    Inventors: Waldemar Debinski, Hetal Pandya, Denise Mazess Herpai
  • Molecular signature of cancer
    Patent number: 9290558
    Abstract: The present invention provides compounds, compositions, and methods for detecting, diagnosing and treating cancers such as glioblastoma multiforme.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: March 22, 2016
    Assignee: Wake Forest University Health Sciences
    Inventors: Waldemar Debinski, Jill Wykosky, Denise Mazess Herpai
  • ANTIBODIES AGAINST HUMAN AND CANINE IL-13RA2
    Publication number: 20160039938
    Abstract: Provided herein is an antibody (e.g., an isolated antibody) that specifically binds an epitope (e.g., linear epitope) within amino acids spanning the extracellular portion of human IL-13RA2. In some embodiments, the amino acids spanning the extracellular portion of human IL-13RA2 have at least 90% identity with the corresponding canine sequence of IL-13RA2. In some embodiments, the antibody specifically binds both human and canine IL-13RA2. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a recombinant antibody. In some embodiments, the antibody is humanized. In some embodiments, the antibody is the monoclonal antibody produced by hybridoma 1E10B9 or a recombinant form thereof.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 11, 2016
    Applicant: Wake Forest University Health Sciences
    Inventors: Waldemar Debinski, Denise Mazess Herpai